Brokers Offer Predictions for Structure Therapeutics Inc.’s FY2022 Earnings (NASDAQ:GPCR)

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Rating) – Equities researchers at SVB Leerink issued their FY2022 earnings estimates for Structure Therapeutics in a report released on Tuesday, February 28th. SVB Leerink analyst D. Risinger expects that the company will earn ($2.12) per share for the year. SVB Leerink has a “Outperform” rating on the stock. SVB Leerink also issued estimates for Structure Therapeutics’ Q4 2022 earnings at ($0.54) EPS, Q1 2023 earnings at ($0.50) EPS, Q2 2023 earnings at ($0.41) EPS, Q3 2023 earnings at ($0.42) EPS, Q4 2023 earnings at ($0.42) EPS, FY2023 earnings at ($1.73) EPS, FY2024 earnings at ($2.05) EPS, FY2025 earnings at $2.72 EPS, FY2026 earnings at ($2.32) EPS and FY2027 earnings at ($2.08) EPS.

A number of other equities analysts have also recently commented on the company. Guggenheim began coverage on Structure Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $50.00 price target on the stock. Jefferies Financial Group began coverage on shares of Structure Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $34.00 target price on the stock. SVB Securities initiated coverage on shares of Structure Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $33.00 price target for the company. Finally, BMO Capital Markets initiated coverage on shares of Structure Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $40.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $39.25.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $22.83 on Thursday. Structure Therapeutics has a 1-year low of $20.80 and a 1-year high of $30.00.

About Structure Therapeutics

(Get Rating)

Structure Therapeutics Inc is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc is based in SAN FRANCISCO.